Supplemental Data for:



Similar documents
ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

FEMALE DRIVER S LICENSE NUMBER STATE ISSUED PLACE OF BIRTH CITY STATE CITY STATE ZIP CITY STATE ZIP COUNTY USA

Limited Pay Policy (L-222B) - Underwriting Guidelines

GUIDE. Prepare for Your Phone Interview and Medical Exam.

Vitamin D. Sources of vitamin D

Coronary Heart Disease (CHD) Brief

Substandard Underwriting Structured Settlements

Known Donor Questionnaire

Summary of the risk management plan (RMP) for Otezla (apremilast)

Form ### Transgender Hormone Therapy - Estrogen Informed Consent SAMPLE

Facing the challenges of CRITICAL ILLNESS

Policy Summary of Friends Life Individual Protection Critical Illness with Life Cover

Policy Summary of Friends Life Individual Protection Critical Illness with Life Cover

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.

Drug Excretion. Renal Drug Clearance. Drug Clearance and Half-Life. Glomerular Filtration II. Glomerular Filtration I. Drug Excretion and Clearance

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

Voluntary Benefits Employee Enrollment and Change Form

Important Information When Considering Portability Coverage

Life Insurance Application

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

We have made the following changes to the Critical Illness events covered under our group critical illness policy.

Orthopaedic Institute of Ohio Demographic Information Date:

Liver Function Essay

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Key Facts about Influenza (Flu) & Flu Vaccine

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

AMERICAN HERITAGE LIFE INSURANCE COMPANY (AHL) 1776 AMERICAN HERITAGE LIFE DRIVE JACKSONVILLE, FLORIDA 32224

AA Critical Illness with Life Cover Policy Summary

U.S. FINANCIAL LIFE INSURANCE COMPANY REQUEST FOR POLICY REINSTATEMENT FOR POLICY #

Weight Loss Surgery and Bariatric Nutrition. Jeanine Giordano, MS, RD, CDN

U.S. FINANCIAL LIFE INSURANCE COMPANY REQUEST FOR POLICY REINSTATEMENT FOR POLICY #

Can You Purchase Life Insurance If You

GROUP DISABILITY INCOME INSURANCE ENROLLMENT

Male New Patient Package

Motor Vehicle Accident - New Patient

CIGI Direct Insurance Services, Inc. QUICK QUOTE CORONARY ANGIOPLASTY/CORONARY BYPASS

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

PATIENT INFORMATION: PATIENT CONTACT PHONE NUMBERS: PHYSICIAN INFORMATION: HEALTH INSURANCE INFORMATION:

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

HEPATIC ENCEPHALOPATHY

Oxygen - update April 2009 OXG

Mansfield*Cosmetic*Surgery*Center* *New*Patient*Welcome*Packet* 817>477>9000* *

Complete coverage. Unbeatable value.

WELCOME Thank you for taking the time to fill out this form. It will enable us to provide quality, personalized dental care for you.

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

How To Pay For Critical Illness Insurance From The Ihc Group

High Blood Cholesterol

Part 3 Disease incidence, prevalence and disability

For customers Friends Life Individual Protection. Childcover benefit

Diabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.

PATIENT REGISTRATION

Medical Matters Action Checklists

Humulin (LY041001) Page 1 of 1

High User Discussion Day. November 19 th, 2012 Nam Bains Health Analytics Branch, HSIMI

Cardiovascular diseases. pathology

Clinically Significant Cardiovascular. Drug Interactions. April 30, 2014 Michael A Militello, PharmD, BCPS Cardiovascular Clinical Pharmacist

Critical Illness Insurance

Medication Utilization. Understanding Potential Medication Problems of the Elderly

How to get the most from your UnitedHealthcare health care plan.

Saint Francis Kidney Transplant Program Issue Date: 6/9/15

Risk Insurance Definitions of the Critical Illness benefits. Dr. Eric Starke Insurance Medical Advisor

Pharmacokinetics: Do we know what we are doing? Prof Dana Niehaus Department of Psychiatry University of Stellenbosch

Understanding Mortality Statistics: The Importance of Cause-of-Death Certification and Coding

BARIATRIC SURGERY PROGRAM APPLICATION Updated: 6/22/2016 Page 1 of 9

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Health Information Form for Adults

Using Family History to Improve Your Health Web Quest Abstract

BSc in Medical Sciences with PHARMACOLOGY

San Luis Dermatology & Laser Clinic, Inc.

How To Lose Weight With Diabetes

Oxygen Therapy. Oxygen therapy quick guide V3 July 2012.

The Impact of Alcohol

Medicare Supplement Application Aetna Life Insurance Company Aetna Administrator, P.O. Box 10374, Des Moines, IA 50306

Diabetes Mellitus Type 2

Guidance for Industry

Health Information Form for Adults

Approach to Abnormal Liver Tests

Completing your Personal Health Application New York Applicants

QSAR. The following lecture has drawn many examples from the online lectures by H. Kubinyi

REGISTRATION FORM PATIENT NAME: ADDRESS (STREET, CITY, STATE, ZIP): HOME PHONE: WORK PHONE: CELL PHONE: DATE OF BIRTH: / / AGE: SEX:

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME

Facts about Diabetes in Massachusetts

Georgia Department of Human Resources BACKGROUND INFORMATION FOR NON-STATE AGENCY CHILD

Viral Hepatitis Case Report

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Dr. Ronnie Pollard, DPM 1563 Gilpin Street Denver, CO

State and National Call Centers

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Managing potential drug-drug interactions to achieve success in HCV triple therapy. David Back University of Liverpool

King County City Health Profile Vashon Island

Drug Interactions with Smoke and Smoking Cessation Medications

Transcription:

Supplemental Data for: Interindividual variability in hepatic OATPs and P-glycoprotein (ABCB1) protein expression: Quantification by LC-MS/MS and influence of genotype, age and sex Bhagwat Prasad, Raymond Evers, Anshul Gupta, Cornelis E.C.A. Hop, Laurent Salphati, Suneet Shukla, Suresh V. Ambudkar and Jashvant D. Unadkat Department of Pharmaceutics, University of Washington, Seattle, P.O. Box 357610, WA 98195, USA (B.P., J.D.U.); Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Rahway, NJ 07065, USA (R.E.); Drug Metabolism and Pharmacokinetics, Infection DMPK, AstraZeneca Pharmaceuticals LLP, Waltham, MA 02451, USA (A.G.); Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, CA, 94080, USA (C.E.H., L.S.); Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA (S.S., S.V.A.)

Supplemental Table 1: Background and demographic information of liver donors. Liver Age (Yr) Sex Ethnicity Liver Cause of Death Donor Medical History Medications at home Pathology HL102 21 Male C Normal Head trauma Normal HL103 15 Female C Normal Head trauma Normal Labetalol HL104 32 Male B(NOH) Fatty Cerebrovascular Epilepsy, ism Phenobarbital, Phenytoin (off for 3 months) HL105 21 Male B(NOH) Normal Head trauma Normal HL106 45 Female C Normal Cerebrovascular Hypothyroid Levothyroxine HL108 42 Female C Normal Brain infarction Normal HL109 46 Male C Fatty Head trauma ism, Obesity, Propranolol HL111 28 Male C Normal Head trauma Normal HL112 28 Male C Normal Head trauma Normal HL113 9 Female C Normal Head trauma Normal HL114 19 Male C Normal Head trauma Normal HL115 52 Female C Normal Subarachnoid Atenolol HL118 25 Male C Fatty Head trauma Depression, multiple drug abuse HL119 24 Male C Normal Head trauma Normal HL120 45 Female C Fatty Cerebrovascular Depression Fluoxetine, Doxepin, Codeine, Promethazine HL121 59 Female C Fatty Subarachnoid Hypothyroid Levothyroxine HL124 51 Female C Fibrosis, cysts Subarachnoid HL125 32 Male C Acute injury Head trauma ism HL126 10 Female C Fatty Respiratory arrest Obesity HL127 38 Male C Normal Head trauma Crypotococcal infection, lung node, at harvest HL128 51 Male C Fatty Head trauma ism HL129 36 Female C Normal, split Subarachnoid Heart transplant in 1990 Cyclosporine A, Azathioprine, liver Prednisone, Nifedipine, Lovastatin HL130 49 Male C Fatty Head trauma Diabetes, ism Insulin, HL131 62 Female C Normal Subarachnoid Prazepine, Indapamide

HL133 45 Female C Fatty Subarachnoid Normal HL134 7 Male C Normal, split Head trauma Normal liver HL135 45 Female C Mild Fatty Cerebrovascular Aneurysm clipping (after injury) HL136 39 Male C Acute injury Head trauma Normal HL137 11 Male B(NOH) Normal, split Head trauma Normal liver HL138 9 Female C Acute injury, Head trauma Normal split liver HL139 15 Female C Normal Head trauma HL140 63 Male C Poorly Head trauma ism perfused HL141 59 Male C Fe deposition? Cerebrovascular ism (abst for 14 yr), atherosclerosis HL142 49 Female C Fatty Subarachnoid ism HL143 48 Male C Fibrotic Cerebrovascular Stroke (8 yrs ago) HL144 68 Female C Fatty Subarachnoid Calcium channel blockers HL145 38 Male C Fibrotic Respiratory arrest Quadriplegia (12 yr), multiple Cimetidine, diazepam, baclofen pneumonias HL146 10 Male C Acute injury Head trauma Normal HL147 70 Female C Fibrotic Cerebrovascular 48 hr smoker; stopped 2 yrs Metoclopramide, Misoprostol ago HL148 60 Female C Fatty Cerebrovascular Fibromyalgia, arthritis Unknown HL149 63 Female C Fibrotic Subarachnoid, heart disease, ism HL150 30 Male C Fatty Cardiac arrest Diabetes, ism, drug abuse (not intravenous), insulin HL151 48 Female C Fatty Subarachnoid Obese, asthma Terfenadine, Hyoscyamine, Pirbuterol, Acetaminophen/codeine, clorazepate HL152 64 Female C Normal Cerebrovascular Hypothyroid Premarin, Levothyroxine, Diazepam HL153 59 Female C Mild Fatty, Subarachnoid Back surgery, alcohol (2-4, Ibuprofen

Fibrotic glass/day) HL154 26 Male C Mild Fatty Head trauma ism, testicular Marijuana, carcinoma HL155 21 Male C Normal Head trauma Normal HL156 44 Male C Fatty Head trauma ism, depression (less recently) HL157 41 Female C Normal, split Subarachnoid Antihypertensives (Unknown) liver HL158 59 Male C Fatty Unknown Unknown Unknown HL159 53 Female C Mild Fatty Unknown Unknown Unknown HL160 67 Male C Fatty Unknown Unknown Unknown HL161 53 Male C Mild Fatty Cerebrovascular ic, palsy symptoms, (1/2 bottle day) psoriasis, sleep apnea HL162 56 Female C Moderate Unknown Unknown Unknown microvesicular fat HL163 55 Male C Mild Fatty Cerebrovascular Untreated HL164 50 Female C Normal CO poisoning Normal HL165 61 Male A Mild Fatty Cerebrovascular Parkinson's since 1990 Drugs for Parkinson's (Unknown) HL166 59 Female C Some fibrosis, Unknown Normal Unknown no fat HL167 44 Male C Normal Unknown Unknown Unknown (excellent) HL168 43 Male C Normal (split Cerebrovascular Unknown liver) HL169 57 Male C Fatty Unknown Normal Unknown HL170 50 Female C Moderate macrovesicular fat Cerebrovascular Epileptic, alcoholic HL171 47 Female C Normal (split) Cerebrovascular HL172 28 Male C Normal (split) Head trauma Untreated, non- IV drug abuse C= Caucasian; B(NOH), black, not of Hispanic origin Phenytoin,, Estrogen, Doxepin, Acyclovir, Cannabis

Supplemental Table 2. Summary of input parameters for OATP1B1 substrates used in Simcyp models Parameter Rosuvastatin Repaglinide Physiochemical properties Mol wt (g/mol) 481.54 452.6 Log P (O:W) 2.4 4.87 Compound type Monoprotic Ampholyte pka 1 4.27 4.19 pka 2 5.78 Blood binding (B/P) 0.625 0.62 Fraction unbound in plasma 0.107 0.023 Absorption Absorption type ADAM ADAM Caco-2 permeability (x10 6 cm/s) 3.395 24.1 Distribution Distribution model Full PBPK model Full PBPK model Elimination HLM Clearance (L/h) 0 128 Vmax (CYP2C8) (pmol/min/mg 300.8 microsomal protein) Vmax (CYP3A4) (pmol/min/mg 958.2 microsomal protein) km (CYP2C8) (µm) 2.3 km (CYP3A4) (µm) 13.2 Renal Clearance (L/h) 17 0.013 Intestinal transporters BCRP (µl/min million hepatocytes)* 18 Hepatic transporters OATP1B1 (µl/min/million hepatocytes)* 109 246 OATP1B3 (µl/million hepatocytes)* 36 OATP2B1+NTCP (µl/million hepatocytes)* 78 BCRP(µl/million hepatocytes)* 1.23 Passive diffusion Clearance (µl/min/10 6 2.5 24 cells) Clearance Int, Bile (µl/min/10 6 cells) 15 0 Relative expression factor (REF) Genotype/haplotype Variant, Mean (90% confidence interval) SLCO1B1 c.388gg 1.8 (1.4, 2.1) 1.0 (0.8, 1.2) SLCO1B1 c.463aa 2.1 (1.6, 2.6) 1.0 (0.9, 1.1) SLCO1B1 c.463ca 1.8 (1.5, 2.1) 1.0 (0.9, 1.1) SLCO1B1 c.597tt 1.7 (1.4, 2.1) 1.0 (0.9, 1.1) SLCO1B1*14/*14 2.2 (1.6, 2.7) 1.0 (0.9, 1.1) SLCO1B1*14/*1a 1.9 (1.6, 2.2) 1.0 (0.9, 1.1) All the values are default from Simcyp library except REF. *Fitted values Wild-type, Mean (90% confidence interval)